CryoLife Hits A 52-Week High: What's Driving The Stock?
Zacks Investment Research | Jun 28, 2017 08:50AM ET
Leading medical device and tissue processing company, CryoLife, Inc. (NYSE:CRY) rallied to a new 52-week high of $20.20 on Jun 27, eventually closing a little lower at $19.65. This represents a positive return of almost 2% over the last six months.
For majority of the last one year, the company’s share price has outperformed the Zacks classified Medical - Instruments sub-industry. The stock has rallied 67.7%, outshining the sub-industry’s gain of 16.3%. Notably, the stock has a market cap of $658.56 million.
Taking the stable performance of the stock into consideration, we expect CryoLife to gain more ground in the coming quarters.
The stock currently has a Zacks Rank #2 (Buy).
CryoLife, Inc. Price and Consensus
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.